Recommendations for bone‐directed therapy in patients with neuroendocrine tumour skeletal metastases at the New Zealand National Neuroendocrine Tumour Multidisciplinary Meeting

The role of anti-resorptive agents in patients with bone metastases from neuroendocrine neoplasms is unclear. Our aim was to review bone-specific treatment recommendations by the New Zealand National Neuroendocrine Tumour Multidisciplinary Meeting (MDM). Recommendations for bone-specific treatment were given at 29/365 MDMs (7.9%); 44.8% were confirmed to have received the recommended therapy. Bone-specific treatment recommendations were infrequent; there is a need for more data on the role of anti-resorptive agents in this group.

Authors

Institutions

Publication Details

Journal
Internal Medicine Journal
Published
2026-01-14
DOI
https://doi.org/10.1111/imj.70268
Primary Topic
Neuroendocrine Tumor Research Advances
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Recommendations for bone‐directed therapy in patients with neuroendocrine tumour skeletal metastases at the New Zealand National Neuroendocrine Tumour Multidisciplinary Meeting

Marianne S. Elston, B. Lawrence, Gayle Radley, Veronica Boyle
Internal Medicine Journal
Neuroendocrine Tumor Research Advances
article

Recommendations for bone‐directed therapy in patients with neuroendocrine tumour skeletal metastases at the New Zealand National Neuroendocrine Tumour Multidisciplinary Meeting

Marianne S. Elston, B. Lawrence, Gayle Radley, Veronica Boyle
article en

Abstract

The role of anti-resorptive agents in patients with bone metastases from neuroendocrine neoplasms is unclear. Our aim was to review bone-specific treatment recommendations by the New Zealand National Neuroendocrine Tumour Multidisciplinary Meeting (MDM). Recommendations for bone-specific treatment were given at 29/365 MDMs (7.9%); 44.8% were confirmed to have received the recommended therapy. Bone-specific treatment recommendations were infrequent; there is a need for more data on the role of anti-resorptive agents in this group.

Internal Medicine JournalVol. 56(3)
University of Auckland (NZ), Auckland University of Technology (NZ), Waikato Regional Council (NZ), Clinical Trials New Zealand (NZ), Waikato District Health Board (NZ), New Zealand Christians in Science (NZ), University of Waikato (NZ)
Good health and well-being
Openalex Percentile: Top 88%
Neuroendocrine Tumor Research Advances
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Recommendations for bone‐directed therapy in patients with neuroendocrine tumour skeletal metastases at the New Zealand National Neuroendocrine Tumour Multidisciplinary Meeting — Marianne S. Elston, B. Lawrence, et al. · Internal Medicine Journal (2026) | TGRS Research Map | TGRS